^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Immunostimulant

    Related drugs:
    2d
    PERS-ACYWX-03: Evaluation of the Antibody Persistence Beyond Five Years After Immunization With MenFiveTM (NmCV-5), a Pentavalent Meningococcal ACYWX Conjugate Vaccine (clinicaltrials.gov)
    P=N/A, N=450, Not yet recruiting, Serum Institute of India Pvt. Ltd.
    New trial
    2d
    SHIELD: Strengthening HPV Immunization Through EPI Leveraged Delivery (clinicaltrials.gov)
    P2, N=115, Not yet recruiting, International Vaccine Institute
    New P2 trial
    2d
    A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age (clinicaltrials.gov)
    P3, N=507, Active, not recruiting, ModernaTX, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    3d
    Application of HBx-based mRNA vaccine (WGc-0201 injection) in liver cancer liver transplantation (ChiCTR2500111513)
    P1, N=12, Not yet recruiting, West China Hospital, Sichuan University; West China Hospital of Sichuan University
    New P1 trial
    3d
    An Exploratory Study of REGEND003 Kidney Progenitor Cells on Patients With Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD) (ChiCTR2500112411)
    P1, N=15, Not yet recruiting, Shanghai Tongji Hospital; Regend Therapeutics
    New P1 trial
    3d
    Evaluation of the Safety and Preliminary Immunogenicity of the Adsorbed Acellular Diphtheria, Tetanus, Pertussis, Inactivated Poliomyelitis, and Haemophilus influenzae Type b (Conjugate) Combined Vaccine in Healthy Infants and Children of Different Ages: A Phase I Clinical Trial (ChiCTR2600117560)
    P1, N=180, Not yet recruiting, Hubei Provincial Center for Disease Control and Prevention; Wuhan Institute of Biological Products Co., Ltd.
    New P1 trial
    3d
    Clinical study to evaluate the safety, tolerability, immunogenicity, and preliminary efficacy of a tumor vaccine targeting specific EGFR mutations as monotherapy and combination therapy in patients with EGFR-mutated non-small cell lung cancer (ChiCTR2500113656)
    P1, N=75, Recruiting, The First Affiliated Hospital of Nanyang Medical College; The First Affiliated Hospital of Nanyang Medical College
    New P1 trial
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M
    |
    Tyvyt (sintilimab)
    3d
    Phase I clinical trial of YKYY031 for injection in patients with advanced solid tumors (ChiCTR2500114935)
    P1, N=76, Not yet recruiting, Beijing Cancer Hospital; Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.
    New P1 trial
    4d
    Live Attenuated Influenza Vaccine as a Nasal Model for Influenza Infection (clinicaltrials.gov)
    P4, N=33, Completed, University of Alabama at Birmingham | Recruiting --> Completed | N=25 --> 33
    Trial completion • Enrollment change
    |
    CFTR (CF Transmembrane Conductance Regulator)
    4d
    Nonavalent Prophylactic HPV Vaccine (GARDASIL9) After Local Conservative The NOVEL Trial (clinicaltrials.gov)
    P3, N=1099, Completed, Imperial College London | Active, not recruiting --> Completed
    Trial completion
    |
    Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant)
    5d
    Oncolytic peptide LTX-315 targets PD-L1 to improve antitumor immune response of nanosecond pulse electric field in liver cancer. (PubMed, J Immunother Cancer)
    LTX-315; Antitumor immune response; nsPEF; Liver cancer.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1)
    |
    PD-L1 expression
    |
    Oncopore (ruxotemitide)
    5d
    Systemic immune correlates of long-term survival after Delta-24-RGD based on the Therapeutic Adenovirus for Recurrent Glioblastoma Effect Trial (TARGET). (PubMed, Clin Cancer Res)
    Immunological fitness, assessed by an anti-adenoviral specific antibody response and higher levels of activated CD8+ NKT-like cells after Delta-24-RGD treatment, may have utility as an early surrogate of a robust systemic immune response that correlates with long-term survival.
    Journal
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma)
    |
    tasadenoturev (DNX-2401)